FDA approves AVITA Medical’s IDE application to assess RECELL system
Category: #health  By Pankaj Singh  Date: 2019-12-30
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA approves AVITA Medical’s IDE application to assess RECELL system

AVITA Medical Limited, a regenerative medicine firm addressing unmet medical needs in therapeutic skin restoration, has reportedly announced that its IDE (Investigational Device Exemption) application to carry out a feasibility study assessing the effectiveness and safety of RECELL System was approved by U.S. FDA (Food and Drug Administration). The company developed this device to help in repigmentation of lesions that are depigmented due to stable vitiligo.

Vitiligo results in loss of pigment, color, in patches of skin that affects the quality of life for people living with these conditions. Currently, there is no treatment available that cures vitiligo, nor a widely accepted method for restricting the progression of the disease. Although, many treatments are being used for the management of vitiligo, they are temporary with a high rate of recurrence.

Speaking on which Mike Perry, CEO, AVITA Medical said that around 6.5 million people are affected by vitiligo in the U.S, rivaling the prevalence of psoriasis. However, there is a lack of treatment options available for patients to restore their skin pigmentation permanently.

Perry added that with this approval, the company will begin its vitiligo study in the two quarters of 2020. Depending upon the results of the feasibility study, the company would proceed with a vital clinical trial to get FDA approval for this device as a cell-based repigmentation therapy for treating stable vitiligo.

Andy Quick, CTO, AVITA Medical said that this study gives published, peer-reviewed effectiveness results to verify RECELL’s feasibility as a treatment for stable vitiligo. RECELL System is widely approved outside of the United States. Over 1,000 patients with vitiligo have been treated worldwide and reported repigmentation, added Quick.

Sources cite that AVITA medical will partner with a renowned medical center to carry a pilot study that would enroll 10 patients that have stable vitiligo lesions for a minimum of one year. Vitiligo lesion areas will be randomly cured with little varying cell suspensions that are prepared with RECELL to confirm optimal suspension parameters and response rates.
 

Source credit: https://www.avitamedical.com/uploads/pdf/AVH-Press-Release-Vitiligo-IDE-Approval-30DEC2019-FINAL.pdf



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Inzomelid declares positive CAPS treatment results, completes Phase I
Inzomelid declares positive CAPS treatment results, completes Phase I
By Pankaj Singh

Inflammasome biotech company Inflazome has reportedly announced the successful completion of Inzomelid’s Phase I clinical study. In addition, the firm has also declared that it has observed positive results from ...

Flipkart to re-open its online portal to deliver essential products
Flipkart to re-open its online portal to deliver essential products
By Pankaj Singh

Flipkart, a renowned Indian e-commerce company, reportedly announced that it would be re-starting its online portal to deliver essential commodities across India. The company had closed down all its operations on Wedne...

American Furniture Warehouse to offer engaging digital receipts
American Furniture Warehouse to offer engaging digital receipts
By Pankaj Singh

American Furniture Warehouse, one of the leading furniture retail firms in the U.S, has reportedly selected flexEngage, a prominent player in personalized transactional communications, for offering dynamic digital rece...